TABLE 4.
SVR12 rates by treatment regimen and viral subtype
| GT4 subtype | SVR12 rates (% [n/N]) in HCV GT4-infected patientsa |
||
|---|---|---|---|
| Treatment naive |
Treatment experienced |
||
| Ombitasvir + paritaprevir/r regimen (N = 44) | Ombitasvir + paritaprevir/r + RBV regimen (N = 42) | Ombitasvir + paritaprevir/r + RBV regimen (N = 49) | |
| All GT4 | 90.9 | 100 | 100 |
| 4a | 100 (21/21) | 100 (13/13) | 100 (16/16) |
| 4d | 81.3 (13/16) | 100 (22/22) | 100 (30/30) |
| 4b, 4c, 4f, 4g/4k, 4o, 4b | 85.7 (6/7)c | 100 (7/7) | 100 (3/3) |
a
n/N = (number of SVR12-achieving patients)/(total number of treated patients).
b
4 = GT4 subtype could not be determined by phylogenetic analysis or the LiPA 2.0 assay.
c
One GT 4b-infected treatment-naive patient prematurely discontinued treatment.